Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.